CDX
JeKo-1
Tumor indication
Lymphoma
Tumor subtype
Mantle Cell Lymphoma
Description
JeKo-1 (Mantle Cell Lymphoma CDX Model)
The JeKo-1 cell line was derived from a patient with mantle cell lymphoma (MCL). It represents an aggressive B-cell non-Hodgkin’s lymphoma. JeKo-1 is commonly used in hematology research and therapeutic evaluation. Its reproducibility makes it a reliable preclinical model for lymphoma studies.
Key Features:
- Derived from mantle cell lymphoma.
- B-cell non-Hodgkin’s lymphoma line.
- Aggressive growth in xenograft systems.
- Suitable for drug screening studies.
Applications:
JeKo-1 supports MCL drug discovery and biomarker validation. It is used to evaluate targeted agents and combination therapies. Researchers study signaling pathways and mechanisms of resistance with this model. Its translational relevance has made it a widely adopted lymphoma model.
Details
- Tumor indication
- Lymphoma
- Tumor subtype
- Mantle Cell Lymphoma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.